Ami Asset Management Lowered Its Adobe (ADBE) Position; Chemocentryx (CCXI) Sellers Decreased By 17.4% Their Shorts

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Chemocentryx Inc (NASDAQ:CCXI) had a decrease of 17.4% in short interest. CCXI’s SI was 1.11M shares in June as released by FINRA. Its down 17.4% from 1.34 million shares previously. With 407,200 avg volume, 3 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 4.64%. The stock decreased 0.92% or $0.08 during the last trading session, reaching $8.58. About 320,229 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since June 11, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI)

Ami Asset Management Corp decreased Adobe Inc. (ADBE) stake by 1.68% reported in 2019Q1 SEC filing. Ami Asset Management Corp sold 1,977 shares as Adobe Inc. (ADBE)’s stock rose 6.38%. The Ami Asset Management Corp holds 115,944 shares with $30.90M value, down from 117,921 last quarter. Adobe Inc. now has $136.79 billion valuation. The stock increased 0.78% or $2.18 during the last trading session, reaching $280.34. About 2.49 million shares traded. Adobe Inc. (NASDAQ:ADBE) has risen 16.13% since June 11, 2018 and is uptrending. It has outperformed by 11.70% the S&P500. Some Historical ADBE News: 03/04/2018 – Adobe Creative Cloud Empowers Creatives to Thrive in the Video Age; 10/04/2018 – GlobalSign Joins Cloud Signature Consortium and Adobe Cloud Signature Partner Program; 28/03/2018 – Adobe Steps Up AI-Powered Marketing to Take on Rivals (Correct); 13/04/2018 – ADOBE SYSTEMS INC – ADDITION OF RICKS EXPANDS ADOBE’S BOARD OF DIRECTORS FROM 10 TO 11 MEMBERS; 21/05/2018 – PERMIRA REPORTS SALE OF MAGENTO COMMERCE TO ADOBE FOR US$1.68B; 21/05/2018 – Adobe To Buy Commerce Platform Magento For $1.68 Billion — MarketWatch; 28/03/2018 – The company’s primary competitor is Adobe; 21/05/2018 – Adobe To Acquire Magento Commerce; 27/03/2018 – ADOBE UNVEILS SYSTEM OF RECORD TO CREATE CONSUMER AD PROFILES; 04/05/2018 – Adobe Named a Leader in 2018 Gartner Magic Quadrant for Multichannel Marketing Hubs

Among 18 analysts covering Adobe (NASDAQ:ADBE), 12 have Buy rating, 0 Sell and 6 Hold. Therefore 67% are positive. Adobe had 29 analyst reports since December 14, 2018 according to SRatingsIntel. The rating was maintained by Cowen & Co on Tuesday, March 12 with “Hold”. The stock has “Market Perform” rating by Cowen & Co on Friday, February 15. Morgan Stanley upgraded the stock to “Overweight” rating in Monday, April 29 report. The stock of Adobe Inc. (NASDAQ:ADBE) has “Hold” rating given on Friday, March 15 by Stephens. The stock of Adobe Inc. (NASDAQ:ADBE) earned “Buy” rating by RBC Capital Markets on Friday, March 15. The rating was maintained by KeyBanc Capital Markets with “Overweight” on Friday, December 14. The firm earned “Buy” rating on Friday, March 15 by Canaccord Genuity. The rating was upgraded by Pivotal Research on Monday, January 7 to “Buy”. On Friday, December 14 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, March 15.

Ami Asset Management Corp increased Matador Res Co Com (NYSE:MTDR) stake by 149,427 shares to 282,774 valued at $5.47 million in 2019Q1. It also upped Fedex Corporation (NYSE:FDX) stake by 52,365 shares and now owns 152,313 shares. Broadridge (NYSE:BR) was raised too.

Since December 19, 2018, it had 1 insider buy, and 9 insider sales for $101.93 million activity. $10.19M worth of Adobe Inc. (NASDAQ:ADBE) was sold by THOMPSON MATTHEW. NARAYEN SHANTANU also sold $34.32M worth of Adobe Inc. (NASDAQ:ADBE) shares. Lewnes Ann had sold 2,692 shares worth $608,539 on Wednesday, December 19. $3.45M worth of Adobe Inc. (NASDAQ:ADBE) was sold by Morris Donna on Friday, February 1. 25,000 shares were sold by Parasnis Abhay, worth $6.00M. $16,244 worth of Adobe Inc. (NASDAQ:ADBE) shares were bought by Ricks David A. Rencher Bradley had sold 30,000 shares worth $7.39 million.

More notable recent Adobe Inc. (NASDAQ:ADBE) news were published by: Finance.Yahoo.com which released: “Hedge Funds Have Never Been This Bullish On Adobe Systems Incorporated (ADBE) – Yahoo Finance” on June 01, 2019, also Nasdaq.com with their article: “Adobe Stock Should Keep Moving Higher – Nasdaq” published on May 23, 2019, Finance.Yahoo.com published: “Should You Be Excited About Adobe Inc.’s (NASDAQ:ADBE) 27% Return On Equity? – Yahoo Finance” on May 15, 2019. More interesting news about Adobe Inc. (NASDAQ:ADBE) were released by: Nasdaq.com and their article: “Adobe Systems (ADBE) Stock Sinks As Market Gains: What You Should Know – Nasdaq” published on June 04, 2019 as well as Nasdaq.com‘s news article titled: “Noteworthy Friday Option Activity: ADBE, ILMN, ISRG – Nasdaq” with publication date: June 07, 2019.

Investors sentiment increased to 1.19 in Q1 2019. Its up 0.26, from 0.93 in 2018Q4. It increased, as 43 investors sold ADBE shares while 371 reduced holdings. 116 funds opened positions while 378 raised stakes. 397.86 million shares or 9.47% less from 439.45 million shares in 2018Q4 were reported. Tower Bridge Advisors invested in 3,640 shares or 0% of the stock. Hemenway Trust Company Llc holds 0.03% or 765 shares in its portfolio. Moreover, Spectrum Management Grp Inc has 0.76% invested in Adobe Inc. (NASDAQ:ADBE). Corvex Mngmt LP accumulated 269,907 shares or 5.02% of the stock. Weiss Asset Mgmt Limited Partnership invested in 787 shares or 0.02% of the stock. Gateway Invest Advisers Lc invested 0.73% in Adobe Inc. (NASDAQ:ADBE). Brighton Jones Limited Liability Corp owns 7,342 shares for 0.24% of their portfolio. Grassi Inv Mgmt accumulated 1,000 shares or 0.04% of the stock. Mufg Americas Corporation invested 0.32% of its portfolio in Adobe Inc. (NASDAQ:ADBE). Canada Pension Plan Board stated it has 0.13% in Adobe Inc. (NASDAQ:ADBE). Eaton Vance Management holds 722,763 shares or 0.44% of its portfolio. Amalgamated Fincl Bank owns 0.48% invested in Adobe Inc. (NASDAQ:ADBE) for 74,206 shares. State Treasurer State Of Michigan stated it has 0.49% in Adobe Inc. (NASDAQ:ADBE). American Group Incorporated invested 0.22% in Adobe Inc. (NASDAQ:ADBE). Johnson Counsel has invested 0.05% in Adobe Inc. (NASDAQ:ADBE).

Analysts await Adobe Inc. (NASDAQ:ADBE) to report earnings on June, 13. They expect $1.41 earnings per share, up 2.17% or $0.03 from last year’s $1.38 per share. ADBE’s profit will be $688.01M for 49.71 P/E if the $1.41 EPS becomes a reality. After $1.37 actual earnings per share reported by Adobe Inc. for the previous quarter, Wall Street now forecasts 2.92% EPS growth.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $498.05 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – ChemoCentryx, Inc. (NASDAQ:CCXI) – Seeking Alpha” on June 05, 2019, also Nasdaq.com with their article: “ChemoCentryx (CCXI) Moves to Buy: Rationale Behind the Upgrade – Nasdaq” published on May 20, 2019, Seekingalpha.com published: “SCYNEXIS and ReWalk Robotics among healthcare gainers; Stellar Biotechnologies and ChemoCentryx among losers – Seeking Alpha” on June 05, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Benzinga.com and their article: “66 Biggest Movers From Yesterday – Benzinga” published on June 06, 2019 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering – Benzinga” with publication date: June 06, 2019.

Since January 7, 2019, it had 0 insider buys, and 5 sales for $1.38 million activity. $74,079 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Cappel Markus J. on Thursday, January 10. KANAYA SUSAN M had sold 37,893 shares worth $457,747. The insider Schall Thomas J. sold $447,092.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *